These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 7957598)
1. Antagonism of clonidine antinociception by buspirone and 1-(2-pyrimidinyl)-piperazine. Cao BJ; Li WP Eur J Pharmacol; 1994 Jun; 259(1):75-8. PubMed ID: 7957598 [TBL] [Abstract][Full Text] [Related]
2. Buspirone and 1-(2-pyrimidinyl)-piperazine attenuate xylazine-induced antinociception in the mouse. Cao BJ; Li WP J Pharm Pharmacol; 1994 Nov; 46(11):931-2. PubMed ID: 7897604 [TBL] [Abstract][Full Text] [Related]
3. Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine--II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission. Blier P; Curet O; Chaput Y; de Montigny C Neuropharmacology; 1991 Jul; 30(7):691-701. PubMed ID: 1681447 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. Berlin I; Chalon S; Payan C; Schöllnhammer G; Cesselin F; Varoquaux O; Puech AJ Br J Clin Pharmacol; 1995 Mar; 39(3):243-9. PubMed ID: 7619663 [TBL] [Abstract][Full Text] [Related]
5. The alpha 2-adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP). Bianchi G; Caccia S; Della Vedova F; Garattini S Eur J Pharmacol; 1988 Jul; 151(3):365-71. PubMed ID: 2905658 [TBL] [Abstract][Full Text] [Related]
6. Comparative behavioural profiles of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze. Cao BJ; Rodgers RJ Neuropharmacology; 1997 Aug; 36(8):1089-97. PubMed ID: 9294974 [TBL] [Abstract][Full Text] [Related]
7. [The pharmacology of 1-(2-pyrimidinyl)piperazine, a metabolite of buspirone]. Komissarov IV; Dulenko VI; Kharin NA; Tolkunov SV; Talalaenko AN Farmakol Toksikol; 1989; 52(2):27-30. PubMed ID: 2568272 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the effect of buspirone and 1-(2-pyrimidinyl)-piperazine on cerebral glucose utilization in the rat. Grasby P; Sharp T; Moorman J; Grahame-Smith D Eur J Pharmacol; 1993 Jan; 230(1):41-6. PubMed ID: 8094054 [TBL] [Abstract][Full Text] [Related]
9. Blockade of alpha 2-adrenoceptors by 1-(2-pyrimidinyl)-piperazine (PmP) in vivo and its relation to the activity of buspirone. Bianchi G; Garattini S Eur J Pharmacol; 1988 Mar; 147(3):343-50. PubMed ID: 2897918 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the anticonflict effect of buspirone and its major metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in rats. Amano M; Goto A; Sakai A; Achiha M; nee Hara ; Takahashi N; Hara C; Ogawa N Jpn J Pharmacol; 1993 Apr; 61(4):311-7. PubMed ID: 8100593 [TBL] [Abstract][Full Text] [Related]
12. [Electroencephalographic study with buspirone, a novel nonbenzodiazepine anxiolytic, and its major metabolite, 1-(2-pyrimidinyl)piperazine (1-PP), in rabbits]. Kawasaki H; Nakamura S; Takasaki K Nihon Yakurigaku Zasshi; 1990 Mar; 95(3):91-104. PubMed ID: 1972369 [TBL] [Abstract][Full Text] [Related]
13. Ipsapirone and 1-(2-pyrimidinyl)-piperazine increase rat locus coeruleus noradrenergic activity. Sanghera MK; Coke JA; Williams HL; McMillen BA Brain Res Bull; 1990 Jan; 24(1):17-22. PubMed ID: 2310943 [TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of the 5-HT(1A) receptor agonist buspirone on stress-induced hyperglycemia in mice: involvement of insulin and a buspirone metabolite, 1-(2-pyrimidinyl)piperazine (1-PP). Sugimoto Y; Takashima N; Noma T; Yamada J Biol Pharm Bull; 2005 Apr; 28(4):733-5. PubMed ID: 15802819 [TBL] [Abstract][Full Text] [Related]
15. Effects of the serotonergic anxiolytic buspirone on plasma glucose and glucose-induced hyperglycemia in mice. Sugimoto Y; Takashima N; Noma T; Yamada J J Pharmacol Sci; 2003 Dec; 93(4):446-50. PubMed ID: 14737015 [TBL] [Abstract][Full Text] [Related]
16. Involvement of supraspinal GABA receptors in majonoside-R2 suppression of clonidine-induced antinociception in mice. Nguyen TT; Matsumoto K; Yamasaki K; Watanabe H Life Sci; 1997; 61(4):427-36. PubMed ID: 9244369 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological evidence for the involvement of 1-(2-pyridinyl)-piperazine (1-PmP) in the interaction of buspirone or gepirone with noradrenergic systems. Giral P; Soubrie P; Puech AJ Eur J Pharmacol; 1987 Jan; 134(1):113-6. PubMed ID: 2881793 [TBL] [Abstract][Full Text] [Related]
18. A metabolite of buspirone increases locus coeruleus activity via alpha 2-receptor blockade. Engberg G J Neural Transm; 1989; 76(2):91-8. PubMed ID: 2565361 [TBL] [Abstract][Full Text] [Related]
19. Oral buspirone causes a shift in the dose-response curve between the elevated-plus maze and Vogel conflict tests in Long-Evans rats: relation of brain levels of buspirone and 1-PP to anxiolytic action. Vaidya AH; Rosenthal DI; Lang W; Crooke JJ; Benjamin D; Ilyin SE; Reitz AB Methods Find Exp Clin Pharmacol; 2005 May; 27(4):245-55. PubMed ID: 16082425 [TBL] [Abstract][Full Text] [Related]
20. The central action of 1-(2-pyrimidinyl)-piperazine, an ipsapirone metabolite. Tatarczyńska E; Pawłowski L; Chojnacka-Wójcik E; Maj J Pol J Pharmacol Pharm; 1989; 41(1):51-61. PubMed ID: 2587437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]